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Background: Surgical resection alone remains suboptimal for pa-
tients with early-stage (I or II) non-small cell lung cancer. Two
similar randomized phase II trials were conducted to define an active
preoperative regimen in this disease state.
Methods: In the first study, patients were randomized to receive
gemcitabine 1000 mg/m2 on days 1 and 8 plus cisplatin 80 mg/m2 on
day 1 (GC) or gemcitabine 1000 mg/m2 on days 1 and 8 plus
carboplatin area under the curve 5.5 on day 1 (GCb). In the second
trial, patients received the same regimen of GCb or gemcitabine
1000 mg/m2 on days 1 and 8 plus paclitaxel 200 mg/m2 on day 1
(GP). Cycles were repeated every 21 days for three cycles. The
primary end point was pathologic complete response (pCR) rate.
Results: Eighty-seven eligible patients were randomized (GC n 
12, GP n  35, and GCb n  40), and 71 (82%) underwent surgery
after chemotherapy. The confirmed pCR rate was 2.3% (2 of 87,
95% confidence interval 0.3–8.1). Clinical response rate was 28.7%,
complete resection rate was 91.5% (65 of 71 patients), and periop-
erative mortality rate was 2.8%. As of October 2006, median
survival for all patients was 45 months (65.5% censored), with
87.2% alive at 1 year and 69.8% alive at 2 years.
Discussion: Neoadjuvant chemotherapy with gemcitabine was fea-
sible and well tolerated, and outcomes were similar to other reports
of this treatment strategy. However, no regimen achieved the pre-
defined pCR rate that would be sufficient to warrant further evalu-
ation in the phase III setting. This trial design provides an efficient
way of providing a rationale for choosing or rejecting regimens of
potential value.
Key Words: Multimodality, Early stage, NSCLC, GINEST, Gem-
citabine, Resectability.
(J Thorac Oncol. 2008;3: 37–45)
Non-small cell lung cancer (NSCLC) remains a leadingcause of mortality throughout the world, accounting for
approximately 80% of the 1.18 million deaths from lung
cancer each year.1,2 Treatment has been determined largely
through diagnostic staging, and curative surgery is indicated
in only a small minority who present with localized disease
without evidence of mediastinal lymph node involvement.3–5
Nonetheless, overall survival (OS) among patients receiving
surgical resection alone remains less than optimal. Among
patients who present with the best clinical prognosis (clinical
T1N0), the 5-year survival rate is 61 to 63% (or 67% based
on pathologic T1N0).6–8
After tumor resection, distant recurrence is the domi-
nant mode of relapse and the most common cause of mortal-
ity. Improved molecular techniques and methods of detection
have confirmed the presence of occult micrometastatic dis-
ease in many patients at the time of resection.9–12 Eradication
of this additional burden forms the rationale for adjuvant and
neoadjuvant strategies in early-stage NSCLC. Several large
early-stage trials have confirmed a modest survival benefit as-
sociated with adjuvant therapy.13–17 Neoadjuvant (preoperative)
therapy theoretically provides the added benefit of tumor down-
staging before surgery, improving the chances of a complete
resection. Nonetheless, experience with preoperative treatment
has concentrated mostly on patients with locally advanced (stage
III), rather than early-stage (I or II) disease.18,19
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A large, randomized French Thoracic Cooperative
Group study (355 patients) showed an 11-month median
improvement in survival with preoperative chemotherapy
compared with surgery alone in stage I to IIIA patients (37 to
26 months, p  0.15).20 When including only patients with
stage I or II disease, the survival benefit of neoadjuvant
therapy was found to be statistically significant (odds ratio 
0.68, p 0.027). A large phase II study in patients with stage
I or II disease also demonstrated the feasibility of the
preoperative approach in early-stage patients.21 Additional
trials also found that downstaging after chemotherapy
predicted improved survival, and patients who had patho-
logic complete response (pCR) to chemotherapy displayed
the best survival.18,22
Gemcitabine (Gemzar, Eli Lilly and Company, India-
napolis, IN) is a pyrimidine antimetabolite23 that has demon-
strated independent antitumor activity in diverse tumor types,
including advanced or metastatic NSCLC.24–26 In advanced-
stage disease, several novel regimens have been used, with no
single treatment strategy demonstrating superior out-
comes.27,28 One of the difficulties in conducting randomized
combined modality trials is that phase III studies often are not
large enough to demonstrate definitive differences even when
provocative results are reported with hundreds of enlisted
patients.20 A series of randomized phase II trials was chosen
as our study design with phase II end points applying to each
treatment arm. This design allows patients to be assigned to
a treatment without investigator bias, and permits a relatively
small number of patients to be enlisted to determine whether
there is a likelihood of either inferior or superior results with
a regimen when seen in the context of currently reported
trials. Thus, more effective regimens can be chosen based
on trial results for further study in larger phase III trials.
Given the need for more effective therapy for stage I and
II disease, the promising results of neoadjuvant trials
(including one randomized study), and the efficacy and
tolerability of gemcitabine-based chemotherapy in ad-
vanced NSCLC, we conducted two similar randomized
phase II trials to better characterize the activity and safety
of chemotherapy regimens.
The pCR rate was chosen as the primary end point
because the results are easily demonstrated and clearly show
the activity of chemotherapy in this setting. Although prior
studies have noted the best survival outcomes in those pa-
tients achieving a pCR from chemotherapy, it must be noted
that in those with stage III extent, it has been easier to achieve
complete clearing of cancer cells in nodal metastases than in
the primary tumor.29
Clinical stage I and II disease was chosen given the data
that neoadjuvant therapy seems to have the greatest benefit in
these stages.20 Stage I was included because of the poor survival
of clinical stage I patients, and because previous studies have
indicated a high incidence of upstaging between clinical and
pathologic stage. We did not exclude stage IA based on a
relatively arbitrary distinction of 3.0 cm or 3.1 cm, but
anticipated that few patients with stage IA would be included,
especially with the need for tissue confirmation of NSCLC.
PATIENTS AND METHODS
Patient Selection
The Gemcitabine in Neoadjuvant Early-Stage Trials
(GINEST) project consisted of two similar phase II trials,
conducted in a total of 23 investigative sites (12 and 11 for
each trial, respectively), involving 87 patients with clinical
stage I or II NSCLC. Patients were required to have a
histologically or cytologically confirmed diagnosis, a nega-
tive mediastinal evaluation (defined as all mediastinal lymph
nodes 1 cm by computed tomography (CT) scan and a
negative positron emission tomography scan; or a negative
mediastinoscopy if either CT or positron emission tomogra-
phy was suspicious), an Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of 0 or 1, age 18
years, and measurable or evaluable disease documented by
chest radiography or contrast-enhanced CT scan (for all
measurable lesions). In addition, patients were required to
have adequate organ function (defined as an absolute granu-
locyte count 1.5  109 cells/liter, platelets 100  109
cells/liter, serum creatinine  1.5 times the institutional
upper limit of normal, and calculated creatinine clearance 
40 ml/min). All patients were required to have a calculated
postresection (ppo) forced expiratory volume in 1 second
40% of the predicted value and a ppo diffusing capacity of
the lung for carbon monoxide (DLCO)/alveolar volume
40% of the predicted value. Prior systemic chemotherapy
or use of other investigational therapy was not allowed;
however, prior resection of lung disease was allowed, pro-
vided 5 years had elapsed before enrollment.
Patients with bronchioloalveolar carcinoma or stage IIB
tumor involving the superior sulcus (Pancoast tumors) were
excluded. In addition, female patients who were pregnant or
nursing, and patients with postobstructive pneumonia or other
serious infection at the time of randomization or any other
serious underlying medical condition that would impair the
ability of the patient to receive treatment were excluded.
Patients were required to provide written informed consent,
and the Institutional Review Boards of participating centers
were required to approve the protocol before study initiation.
Trial Design and Treatment Plan
Schemas for the GINEST project are summarized in
Figure 1. Patients were randomized to receive neoadjuvant
therapy in one of two similar, multicenter, phase II clinical
trials. Patients in the first trial were randomized to receive
gemcitabine 1000 mg/m2 on days 1 and 8 followed by
cisplatin 80 mg/m2 or carboplatin at area under the curve
(AUC) 5.5 on day 1. Patients in the second trial were
randomized to receive gemcitabine 1000 mg/m2 on days 1
and 8 followed by paclitaxel 200 mg/m2 or carboplatin at
AUC 5.5 on day 1. Treatment cycles were repeated every 21
days for 3 cycles. Carboplatin dosing was based on the
formula described by Calvert et al.30 All therapies were
administered intravenously; gemcitabine over 30 minutes,
cisplatin over 30 to 90 minutes, carboplatin over 30 minutes,
and paclitaxel over 60 minutes.
Before chemotherapy, if neutrophils were 1.5  109
cells/liter or platelets 100,000, chemotherapy doses of all
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therapies were to be reduced by half. If neutrophils were
1.0  109 cells/liter or platelets 50,000, chemotherapy
was to be delayed until sufficient recovery. Guidelines for
dose adjustments were also provided in the event of febrile
neutropenia, bleeding, cisplatin-related nephrotoxicity, or cis-
platin- or paclitaxel-related neurologic toxicity.
Surgery
Between 2 and 6 weeks after the last dose of chemo-
therapy, patients underwent resection. In addition, patients
with clear evidence of progressive disease (PD) before the
third cycle of therapy could proceed to surgery, if resectable.
Every effort was made to carry out a complete resection (R0).
Extent of resection (lobectomy, bilobectomy, or pneumonec-
tomy) was performed on the basis of the prechemotherapy CT
scan. Surgical resection included a systematic sampling of
mediastinal lymph nodes in each ipsilateral and subcarinal
nodal station (2, 4, 7, 9 on the right and 4, 5, 7, 9 on the left).
Level 10 hilar nodes were also included. If no nodes could be
found after opening the pleura and exploration of a nodal
station, then this station was classified as negative.
Evaluations
The search for residual tumor after induction chemo-
therapy was carried out as was routinely performed in the
particular institution. No extra techniques or sectioning were
required. pCR was defined as no viable tumor cells in the
specimen, as determined by light microscopy. The operative
notes of all pCR and near-pCR cases were centrally reviewed
to assure that the quality of surgery was appropriate, and if a
pCR was either reported or felt to be likely, then the tissue
was examined by a central referee pathologist (M.B.Z.).
During chemotherapy, physical examination, blood
chemistry, PS evaluation, and chest radiography were per-
formed before each cycle. At the end of each cycle, toxicity
was evaluated according to National Cancer Institute com-
mon toxicity criteria. At the end of induction therapy, a CT
scan was performed and pulmonary function reassessed. If
there was a drop of 20% in forced vital capacity or DLCO,
patients underwent additional investigation. To be eligible for
surgery, patients needed to have either a ppo forced expira-
tory volume in 1 second and ppo DLCO/VA 40% or an
exercise test with a VO2max 15 ml/kg/min. Surgical mor-
bidity was defined as any common toxicity criteria grade 3 or
4 event occurring within 30 days of surgery that the investi-
gator believed was related to surgery.
Statistical Analysis
The primary end point of the study was the pCR rate;
patients evaluable for this calculation included all who un-
derwent resection as well as patients who were removed from
the study before resection because of clear evidence of
disease progression after treatment with at least one cycle of
chemotherapy. Other end points of this study included clin-
ical response (CR) rate, OS, and disease-free survival (DFS).
These end points were assessed in the intent-to-treat (ITT)
population, defined as all patients who were enrolled and
eligible, regardless of what treatment was actually received.
Secondary end points also included toxicity and operative
mortality. Toxicity was assessed in all patients who received
at least one cycle of chemotherapy (designated as the safety
population). Pulmonary toxicity was evaluated in detail and
will be the subject of a separate publication. Operative mor-
tality was assessed in all patients who underwent surgery with
the intent to resect. Finally, secondary end points also in-
cluded preoperative and postoperative quality of life, which
will also be reported in a separate publication.
Complete CR was defined as the radiographic disap-
pearance of all known disease, determined by two observa-
tions not less than 3 weeks apart. Partial response (PR) was
defined as a 50% decrease in bidimensional measurements
of the lesions that have been measured to determine the effect
of therapy by two observations 3 weeks apart. In addition,
there had to be no appearance of new lesions or progression
of any lesion. PD was at least a 25% increase in the bidi-
mensional measurements of at least one measurable lesion or
the appearance of new lesions. Survival and DFS were
assessed from the date of randomization to the date of death
or progression. Although the randomized phase II design of
these studies did not allow direct comparison of the treatment
arms, it provided data for the evaluation of the activity and
relative toxicities of the regimens.
Both studies used the same two-stage design for each
treatment arm, as randomized phase II trials. Initially, 15
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Trial #1:
Cisplatin 80 mg/m2
D 1
Gemcitabine 1000 mg/m2
D 1,8
q 21 D x 3
Carboplatin AUC 5.5 
D 1
Gemcitabine 1000 mg/m2
D 1,8
q 21 D x 3
Arm B:
Carboplatin AUC 5.5 
D 1
Gemcitabine 1000 mg/m2
D 1,8
q 21 D x 3
Paclitaxel 200 mg/m2   
D 1
Gemcitabine 1000 mg/m2
D 1,8
q 21 D x 3
Arm A:
Arm B:
Trial #2:
Preop chemo in 
stage I, II NSCLC
Preop chemo in 
stage I, II NSCLC
Arm A:
FIGURE 1. The GINEST project schema.
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patients were enrolled in each treatment arm and pathologic
response rate was assessed at the time of surgery. If at least
1 of 15 patients in an arm showed a complete pathologic
response, then accrual in that arm was expanded to 35
patients to better characterize the true pCR rate for that
treatment regimen. If complete pathologic response was seen
in none of the first 15 treated, then that arm was closed. With
no response in 15 patients (a 0% observed rate), it was
concluded that the regimen is associated with a true pCR rate
of 20% at   0.05, which is below our predetermined
minimum pCR rate. Accrual was continued in other treatment
arms independent of the closure of that treatment arm. If at
least one pCR was found in the initial 15 patients, an
additional 20 patients were added to further characterize the
pCR rate. This was to further test whether the regimen had a
true pCR rate of20% at  0.05. If the observed pCR rate
was higher in the 35 patients, the regimen would be of
sufficient interest to pursue further.
The planned sample size for each of the two indepen-
dently conducted studies was estimated at 30 to 70 patients
per arm, depending on the activity or the regimens, as
discussed earlier. However, the first trial was discontinued
after enrolling 28 patients as a result of slow patient accrual
(12 were randomized to receive gemcitabine cisplatin [GC]
and 16 received gemcitabine  carboplatin [GCb]). In the
second trial, enrollment reached 54 patients (24 received GCb
and 35 received gemcitabine  paclitaxel [GP]). This trial
was stopped at this point because the GP arm had reached full
accrual and 35 patients had received GCb when both trials
were taken together. With the nearly identical study design
for each of these phase II studies, for the purpose of statistical
analysis, the GCb arms from the two trials were combined
because of the identical nature of patient eligibility criteria
and treatment plans between the two studies.
RESULTS
Patients
Between June 2001 and December 2004, 87 patients
with stage I or II NSCLC were accrued at 16 investigational
centers in the United States. Twelve patients were assigned to
GC, 35 were assigned to GP, and 40 were assigned to GCb.
All 87 patients received at least one dose of study drug.
Baseline characteristics and patient disposition for all three
treatment groups are summarized in Table 1. Median age of
all patients was 63 years, and most (75%) had an ECOG PS of
0. Almost half (49%) of all patients had stage IB (T2N0) disease.
Among all patients, 39% were diagnosed with squamous cell
carcinoma, 36% with adenocarcinoma, 17% with disease not
otherwise specified, and 2% with large cell carcinoma.
Comparison of GCb Groups
Characteristics and outcomes from the GCb groups of
the two trials were similar. In comparing patients from trial 1
(n  16) versus trial 2 (n  24), median age was 62.0 versus
63.5 years, 93.7% versus 75% had an ECOG PS of 0, 50%
versus 50% had adenocarcinoma, and 81.3% versus 62.5%
had stage I disease, respectively. In addition, 18.8% versus
20.8% had a PR, 43.8% versus 45.8% had grade 3 or 4
leukopenia, and 12.5% versus 20.8% had grade 3 or 4
thrombocytopenia, respectively. Given the observed similar-
ities between the two GCb groups (none of the differences in
efficacy or toxicity parameters between GCb groups were
statistically significant) it seemed reasonable to combine the
two for analysis.
Of the 87 patients enrolled in the study, 249 cycles of
treatment were administered, a mean of 2.9 cycles per patient.
Among all patients, the mean number of doses for gemcitab-
TABLE 1. Baseline Characteristics and Disposition (Intent-
to-Treat Population, n  87)
GC (n  12) GP (n  35) GCb (n  40)
Median age, yr (range) 61.5 (42–83) 63.0 (33–79) 63.5 (36–82)
Gender
Male 5 (41.7) 20 (57.1) 21 (52.3)
Female 7 (58.3) 15 (42.9) 19 (47.5)
ECOG PS
0 8 (66.7) 24 (68.6) 33 (82.5)
1 4 (33.3) 11 (31.4) 7 (17.5)
Histology
Squamous 5 (41.7) 17 (48.6) 12 (30.0)
Adenocarcinoma 5 (41.7) 6 (17.1) 20 (50.0)
NSCLC, NOS 2 (16.7) 9 (25.7) 4 (10.0)
Large-cell
undifferentiated
0 (0) 0 (0) 2 (5.0)
Other 0 (0) 3 (8.6) 2 (5.0)
Clinical stage
IA (T1N0) 2 (16.7) 6 (17.1) 10 (25.0)
IB (T2N0) 7 (58.3) 18 (51.4) 18 (45.0)
IIA (T1N1) 0 (0) 0 (0) 3 (7.5)
IIB (T2N1, T3N0) 3 (25.0) 11 (31.4) 9 (22.5)
Cycles administered
One 12 (100) 35 (100) 40 (100)
Two 10 (83.3) 32 (91.4) 40 (100)
Three 9 (75.0) 31 (88.6) 40 (100)
Surgical population 9 (75.0) 29 (82.9) 33 (82.5)
Type of resection
Upper lobe right 2 (22.2) 8 (27.6) 9 (27.3)
Middle lobe right 2 (22.2) 3 (10.3) 3 (9.1)
Lower lobe right 1 (11.1) 3 (10.3) 2 (6.1)
Upper lobe left 2 (22.2) 9 (31.0) 10 (30.3)
Lower lobe left 1 (11.1) 2 (6.9) 4 (12.1)
Central right 1 (11.1) 3 (10.3) 3 (9.1)
Central left 1 (11.1) 2 (6.9) 3 (9.1)
Multiple lobes 0 (0.0) 1 (3.4) 1 (3.0)
Discontinuations
Study completed 9 (75.0) 28 (80.0) 33 (82.5)
Adverse event 2 (16.7) 2 (5.7) 0 (0)
Death due to
unknown cause
0 (0) 0 (0) 1 (2.5)
Distant recurrence 0 (0) 2 (5.7) 1 (2.5)
Patient decision 1 (8.3) 0 (0) 0 (0)
Other 0 (0) 3 (8.6) 5 (12.5)
Values given are n (%) values, unless indicated otherwise.
NOS, not otherwise specified; NSCLC, non-small cell lung cancer; PS, perfor-
mance status.
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ine was 5.2 (of planned six doses) and the mean number of
doses for cisplatin, paclitaxel, or carboplatin was 2.8 (of three
planned doses). Primary reasons for premature discontinua-
tion included adverse event (n  4), distant disease recur-
rence (n  3), death (n  1), and patient decision (n  1).
Seventy one patients (82%) underwent surgery, consisting of
similar rates of patients from all three treatment groups. In the
surgical population, upper lobe left (29.6%) and upper lobe
right (26.8%) were the most common types of localization.
Most cycles of chemotherapy were fully administered
during three cycles of therapy. Among all patients, median
relative dose intensity was 97.5% for gemcitabine, 98.1% for
cisplatin, 98.0% for paclitaxel, and 99.2% for carboplatin.
Compared with other treatment groups, however, GCb had
the highest percentage of patients with dose reductions,
delays, and omissions. In the GC group, only one dose
reduction occurred (8.3%). In the GP group, 11 of the 35
patients receiving therapy (31.4%) received dose reductions.
By comparison, of the 40 patients receiving GCb, 22 had dose
reductions (55.0%). Three doses were delayed in the GC
group (25.0%), four doses were delayed in the GP group
(11.4%), and 22 doses were delayed in the GCb group
(22.5%). There were a total of six dose omissions in the GC
group (50%), 13 dose omissions in the GP group (37.1%),
and 26 dose omissions in the GCb group (65.0%).
Toxicity
All 87 patients were evaluated for safety. Results are
summarized in Table 2. Grade 3 or 4 hematologic and
nonhematologic events occurred with a low frequency; the
most common event in any treatment group was leukopenia
(grade 3  35.0% and grade 4  10.0% of patients in GCb).
Alopecia most frequently occurred in the GP group (42.9%
versus 8.3% in the GC group and 5.0% in the GCb group).
Other grade 2 events, including arthralgia, dyspnea, diarrhea,
asthenia, and myalgia were more frequent in the GP group.
Response to Neoadjuvant Chemotherapy
The overall CR rate for all 87 patients was 28.7% (95%
confidence interval [CI] 19.5–39.4) including one patient
(1.1%) with CR, 24 with PR (27.6%), 39 with stable disease
(SD; 44.8%), and 8 with PD (9.2%). The single CR occurred
in a patient from the GC treatment group. The overall re-
sponse rates for each treatment group were 41.7% for GC
(95% CI 15.2–72.3), 34.3% for GP (95% CI 19.1–52.2), and
20.0% for GCb (95% CI 9.1–35.7).
Surgical Procedures and Outcomes
Table 3 summarizes surgical procedures and outcomes
of surgery. Of the 87 patients assessable for resection, 71
underwent surgery (82%). Surgical procedures performed
were lobectomy (n  49), pneumonectomy (n  12), bilo-
bectomy (n  8), and other procedures (n  2).
Complete resections in those going to surgery oc-
curred in 91.5% of patients (65 of 71; 95% CI 82.5–96.8),
with five patients undergoing incomplete resection and one
undergoing grossly incomplete resection. In all patients
entered into the trial, 74.7% had complete resection (65 of
87, 95% CI 64–83.4). Resectability rate was not statisti-
cally different across treatment arms. Perioperative mor-
TABLE 2. Preoperative Hematologic and Nonhematologic Toxicity (Safety Population,
n  87)a
GC (n  12) GP (n  35) GCb (n  40)
G3 G4 G3 G4 G3 G4
Hematologic
Anemia
Leukopenia 6 (17.1) 1 (2.9) 14 (35.0) 4 (10.0)
Thrombocytopenia 4 (10.0) 3 (7.5)
Nonhematologic
Alopecia (G2 only) 1 (8.3) 15 (42.9) 2 (5.0)
Arthralgia 3 (8.6)
Asthenia 1 (2.9) 1 (2.5)
Cellulitis 1 (2.9) 1 (2.5)
Chest pain 1 (2.9) 1 (2.5)
Constipation
Diarrhea 1 (2.9) 1 (2.5)
Dyspnea 1 (2.9)
Myalgia 1 (2.9)
Neurotoxicity 2 (16.7) 2 (5.7)
Rash 1 (8.3)
Vomiting
Values given are n (%) values, unless indicated otherwise.
a Blank cells indicate a frequency of 0 (0.0%).
G  NCI CTC grade.
GC  gemcitabine-cisplatin.
GP  gemcitabine-paclitaxel.
GCb  gemcitabine-carboplatin.
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tality occurred in two patients (2.8%), subsequent to one
lobectomy and one pneumonectomy. The most common
grade 3 or 4 postoperative adverse events (within 30 days)
were pain and dyspnea (9.9% each), followed by atrial
fibrillation and infection (2.8% each), and other events
occurring in one patient each.
Pathologic Response
Two confirmed pCRs were observed in this study, both
of which were in the GP treatment group. The overall con-
firmed pCR rate was 2.3% (2 of 87 patients, 95% CI 0.3–8.1).
One patient with a pCR had stage I disease, and one had stage
II disease. By treatment arm, pCR rate was 0% (95% CI
0.0–33.6) for GC, 6.9% (95% CI 0.8–22.8) for GP, and 0%
(95% CI 0.0–10.6) for GCb.
Survival and DFS
OS by treatment administered is summarized in Figure
2A. As of October 2006, 35% of patients with at least one
follow-up visit (30 of 87) had died. Censoring at the date of
last follow-up visit for the patients who were still alive,
median OS was 45 months (95% CI 35.5 to not evaluable
[NE]). For all patients, 1-year survival was 87.2% (95% CI
80.1–94.3), and 2-year survival was 69.8% (95% CI 59.5–
80.1). Median OS was NE (95% CI 17.3 to NE) for patients
who had received GC, NE (95% CI 31.2 to NE) for patients
who had received GP, and 42 months (95% CI 20.5 to NE)
for patients who had received GCb.
Figure 2B summarizes OS by clinical disease stage. Of
the 61 patients with stage I disease, OS was NE (95% CI 35.5
to NE). Of the 26 patients with stage II disease, OS was 31
months (95% CI 15.2 to NE). The censorship rate was 68.9%
for patients with stage I disease and 57.7% for patients with
stage II disease. Survival at 1 year was 88.4% (95% CI
80.3–96.5) for patients with stage I disease and 84.4% for
patients with stage II disease. Two-year survival was 73.1%
(95% CI 61.4–84.9) for patients with stage I disease and
61.9% (95% CI 41.9–82.0) for patients with stage II disease.
DFS is summarized in Figure 3. Overall, median DFS
was 27 months (95% CI 19.4–38.6; 48% censored). Median
TABLE 3. Surgical Procedures and Outcomes (Patients with
Tumor Resection, n  71)
Procedure
Lobectomy 49 (69.0)
Pneumonectomy 12 (16.9)
Bilobectomy 8 (11.2)
Other 2 (2.8)
Outcome
Complete resection (R0) 65 (91.5)
Incomplete resection (R1) 5 (7.0)
Grossly incomplete resection (R2) 1 (1.4)
Pathologic stage
Complete response (T0N0) 2 (2.8)
IA (T1N0) 17 (23.9)
IB (T2N0) 26 (36.6)
IIA (T1N1) 4 (5.6)
IIB (T2N1, T3N0) 14 (19.8)
IIIA (T3N1, T2N2) 3 (4.2)
IIIB (T4N0, T4N2, T4NX) 3 (4.2)
Missing 2 (2.8)
Perioperative mortality 2 (2.8)
Morbidity within 30 d
Pain 7 (9.9)
Dyspnea 7 (9.9)
Atrial fibrillation 2 (2.8)
Infection 2 (2.8)
Sepsis 1 (1.4)
Ascites 1 (1.4)
Hypotension 1 (1.4)
Constipation 1 (1.4)
Ileus 1 (1.4)
Apnea 1 (1.4)
Hypoxia 1 (1.4)
Pneumonia 1 (1.4)
Pneumothorax 1 (1.4)
Delirium 1 (1.4)
Values given are n (%) values.
FIGURE 2. A, Overall survival stratified by treatment admin-
istered. Black: gemcitabine/cisplatin (n  12), Red: gemcit-
abine/paclitaxel (n  35), Blue: gemcitabine/carboplatin
(n  40). B, Overall survival stratified by clinical stage I (n 
61) or stage II (n  26) disease. Black: stage I, Red: stage II.
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DFS was NE (95% CI 8.6 to NE) for GC, 27 months (95% CI
13.8 to NE) for GP, and 27 months (95% CI 12.6 to NE) for
GCb. For all patients, 1-year DFS rate was 72.1% (95% CI
61.0–82.7). By treatment group, 1-year DFS rate was 72.7%
for GC, 74.3% for GP, and 69.9% for GCb. For all patients,
2-year DFS was 57.4% (95% CI 44.4–70.4), with rates of
72.7% for GC, 51.5% for GP, and 51.5% for GCb.
DISCUSSION
Although the overall outcomes available to date in this
largely stage IB and stage IIB population are competitive
with older trials, the pCR rate when examined as a prospec-
tive end point was low, and did not meet the target rate
established for these studies. Nonetheless, these studies indi-
cate that even relatively small randomized phase II trials in
this setting can characterize the activity of chemotherapy
regimens in combined modality settings. The randomized
phase II design demonstrated the safety of neoadjuvant che-
motherapy as part of either a platinum or nonplatinum dou-
blet, in terms of chemotherapy induction and in the operative
safety. Although the design of these independently conducted
studies prevented formal statistical comparison of treatment
arms, the studies did provide data to assess the activity and
the relative toxicities of the three regimens.
For patients undergoing surgery, complete resection
rate was 91.5%, which compares with the 89.6% rate reported
by Depierre et al.,20 and the perioperative mortality rate of
2.8% in this study was in the low range of previously reported
studies.20,31,32 As a percentage of the overall ITT population,
the complete resection rate was 74.7%, which was lower than
the 85.3% rate reported in the Depierre et al. study.20 The
collective results support the premise that preoperative ther-
apy might complement surgical outcomes. Postsurgical mor-
bidity rates were low and comparable across treatment
groups. Pain and dyspnea were the most common events
within 30 days of surgery.
All three treatment regimens demonstrated clinical ac-
tivity. CR rates, however, were variable across treatment
groups, ranging from 20.0% for GCb to 41.6% with GC.
These response rates compare with the 41% rate reported in
Southwest Oncology Group (SWOG) 9900.33 The intent of
this trial design was not to evaluate the included regimens
against each other; instead the design was to explore the value
of each regimen for use in potential future trials. Recent
meta-analyses have indicated higher response34 and survival
rates34–36 with third-generation regimens using cisplatin ver-
sus carboplatin in patients with advanced disease. In all
patients, survival rates of 87.2% at 1 year and 69.8% at 2
years were promising. Similar studies have reported 1-year
survival rates ranging from 69 to 85% and 2-year survival
rates ranging from 56 to 65%.37–41 SWOG 9900, which had
a ratio of stage I:II disease of 70%:30%, did seem to be the
closest match to the current study. An interim report from that
study showed a 2-year survival rate of 69% among patients
treated in the neoadjuvant setting.33 Because of high censor-
ship at the time of data capture, the median survival of 45
months among all patients from the current report was likely
underestimated.
Of the three regimens used, GCb was associated with
the greatest percentage of patients with dose adjustments and
myelosuppression. In contrast, GP was associated with in-
creased alopecia, and GC was associated with increased
neurotoxicity. Few grade 4 events occurred in GC or GP, and
grade 4 leukopenia and thrombocytopenia occurred with
frequencies of 10.0% and 7.5% in GCb, respectively. A
recent analysis of 1126 patients receiving front-line GCb in
randomized trials found that patients receiving carboplatin at
AUC 5 experience approximately half the incidence of grade 4
neutropenia and thrombocytopenia as patients receiving carbo-
platin at AUC 5.5, without compromising clinical activity.42 It is
possible that the tolerability of GCb in this study could have
been improved by dosing carboplatin at an AUC of 5.
Previous studies have correlated pCR rate with survival
in neoadjuvant studies.37 The importance of pCR implies that
marked effect on large tumor deposits may translate to an
effect on micrometastases. Theoretically, only through con-
trol of micrometastatic disease (present in 90% or more of
stage III patients, and in more than 20% of stage I patients)10
can long-term survival for a large number of patients be
expected. Thus, improvement of pCR rates through use of
systemic therapy is a desired goal in combined modality
treatment, and serves as a stringent surrogate marker for the
ability to eradicate occult distant metastases.
Unfortunately, the pCR rate observed in the current
studies (2.8%) was low. Previous studies of neoadjuvant
therapy have produced pCR rates ranging from 6 to
19%.20,21,29,37 Explanations for low pCR rates in prior studies
have focused on the number of cycles administered. How-
ever, the Depierre et al. trial20 used only two cycles of
treatment and the Martini et al. trial29 used either two or three
cycles, and the PCR rates in these trials were similar for both
groups (11% versus 13%, respectively). Curiously, trials with
higher pCR rates included patients with stage III disease,
whereas the Pisters et al. trial, which included only patients
with stage I or II disease, reported a pCR rate of 6%.39 It is
possible that pCR rates may generally be overestimated. It
FIGURE 3. Disease-free survival by treatment administered.
Black: gemcitabine/cisplatin (n  12), Red: gemcitabine/
paclitaxel (n  35), Blue: gemcitabine/carboplatin (n  40).
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may not be surprising that when pCR is prospectively the
primary end point and is checked by an independent reference
pathologist with prior experience in this area, the verified
pCR rate is lower than anticipated.
Ramnath et al. recently reported the results of a phase
II study of induction therapy with gemcitabine and vinorel-
bine in resectable (stage IB to IIIa) NSCLC (n  62).40 The
authors noted that the treatment effect of this combination
produced a lower response rate, but an improved toxicity
profile, and comparable survival compared with platinum
regimens. Ramnath et al. reported a pCR rate similar to that
of the current study (2%). Martin et al. also noted promising
survival data despite a pCR rate of 4.5% in resectable pa-
tients.38 At the 2007 American Society of Clinical Oncology
Annual Meeting, Felip et al. reported preliminary results from
the Neoadjuvant Taxol/Carboplatin Hope trial.43 Among the
patients receiving neoadjuvant treatment in the trial, the pCR
rate was 9%, and 75% had pathologic N0-1 disease (com-
pared with 73.6% N0-1 in the ITT population of our studies).
Given that none of the trials summarized earlier achieved the
20% pCR rate prospectively defined by our statistical meth-
ods, it is likely that this goal was overambitious.
The randomized phase II trial design used permitted
three regimens to be explored for possible incorporation into
future phase III trials. The characterizations of these regimens
in patients with stage I and II extent allowed for a rational
basis to select or reject particular regimens for larger trials.
We feel that this same design will allow other regimens,
perhaps adding molecularly targeted agents or based on
patient pharmacogenomics, to be explored for suitability for
use in neoadjuvant settings. The current trials were troubled
by slow patient accrual, especially in the smaller trial. One
reason for this was the presentation of positive results from
adjuvant studies, which was felt to have had a similar impact
of slow accrual on the early-stage neoadjuvant SWOG 9900
trial as well.
The current report focuses on reporting standard clini-
cal end points. Patient end points related to quality of life and
pulmonary function were also prospectively collected in pa-
tients enrolled in these trials. These analyses will be included
in future reports, which may provide additional insight with
respect to treatment options. We feel that this trial design is
an efficient and practical approach to examining different
chemotherapy regimens in a combined modality setting.
Clearly, the information derived from several large, random-
ized studies, such as SWOG 9900,33 and the Neoadjuvant
Taxol/Carboplatin Hope trial,43 will be of great interest al-
though the LU22 trial recently reported negative results.44
Mature results from these studies will further delineate the
role of neoadjuvant therapy in early-stage NSCLC.
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